Active Ingredient History

NOW
  • Now
Tamoxifen (brand name Nolvadex), is selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen itself is a prodrug, having relatively little affinity for its target protein, the estrogen receptor (ER). It is metabolized in the liver by the cytochrome P450 isoform CYP2D6 and CYP3A4 into active metabolites such as 4-hydroxytamoxifen (4-OHT) (afimoxifene) and N-desmethyl-4-hydroxytamoxifen (endoxifen) which have 30–100 times more affinity with the ER than tamoxifen itself. These active metabolites compete with estrogen in the body for binding to the ER. In breast tissue, 4-OHT acts as an ER antagonist so that transcription of estrogen-responsive genes is inhibited. Tamoxifen has 7% and 6% of the affinity of estradiol for the ERα and ERβ, respectively, whereas 4-OHT has 178% and 338% of the affinity of estradiol for the ERα and ERβ. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects. Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer in pre- and post-menopausal women. Additionally, it is the most common hormone treatment for male breast cancer. Patients with variant forms of the gene CYP2D6 (also called simply 2D6) may not receive full benefit from tamoxifen because of too slow metabolism of the tamoxifen prodrug into its active metabolites. Tamoxifen is used as a research tool to trigger tissue-specific gene expression in many conditional expression constructs in genetically modified animals including a version of the Cre-Lox recombination technique. Tamoxifen has been shown to be effective in the treatment of mania in patients with bipolar disorder by blocking protein kinase C (PKC), an enzyme that regulates neuron activity in the brain. Researchers believe PKC is over-active during the mania in bipolar patients.   NCATS

  • SMILES: CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3
  • InChIKey: NKANXQFJJICGDU-QPLCGJKRSA-N
  • Mol. Mass: 371.52
  • ALogP: 6.0
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.0758 - $10.1360

Australia

$0.2005 - $0.2007
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene | 1-p-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene | citofen | crisafeno | diemon | emblon | fentamox 10 | fentamox 20 | ici-46474 | istubol | kentadex | kessar | kessar 10 | kessar 20 | noltam | nolvadex | nolvadex d | nolvadex fte | nourytam | oestrifen-10 | oestrifen-20 | oestrifen-40 | oncomox | retaxim | soltamox | tamofen | tamoxasta | tamoxifen | tamoxifen citrate | tamoxifene | tamoxifène | tamoxifene citrate | tamoxifeno | tamoxifenum | trans-tamoxifen | valodex | (z)-2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethanamine | (z)-2-(para-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylamine | zemide | zynoplex

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue